AC Immune S.A.
ACIU · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $27,309 | $14,801 | $3,935 | $0 |
| % Growth | 84.5% | 276.1% | – | – |
| Cost of Goods Sold | $62,570 | $54,606 | $0 | $0 |
| Gross Profit | -$35,261 | -$39,805 | $3,935 | $0 |
| % Margin | -129.1% | -268.9% | 100% | – |
| R&D Expenses | $62,570 | $54,606 | $60,336 | $62,282 |
| G&A Expenses | $11,434 | $10,576 | $9,582 | $10,879 |
| SG&A Expenses | $11,434 | $10,576 | $9,582 | $10,879 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$56,887 | -$51,363 | $4,864 | $5,849 |
| Operating Expenses | $17,117 | $13,819 | $74,782 | $79,010 |
| Operating Income | -$52,378 | -$53,624 | -$70,847 | -$79,010 |
| % Margin | -191.8% | -362.3% | -1,800.4% | – |
| Other Income/Exp. Net | $1,465 | -$599 | $107 | $6,017 |
| Pre-Tax Income | -$50,913 | -$54,223 | -$70,740 | -$72,993 |
| Tax Expense | $3 | $10 | $13 | $3 |
| Net Income | -$50,916 | -$54,233 | -$70,753 | -$72,996 |
| % Margin | -186.4% | -366.4% | -1,798% | – |
| EPS | -0.51 | -0.64 | -0.85 | -0.97 |
| % Growth | 20.3% | 24.7% | 12.4% | – |
| EPS Diluted | -0.51 | -0.64 | -0.85 | -0.97 |
| Weighted Avg Shares Out | 99,692 | 84,695 | 83,554 | 74,952 |
| Weighted Avg Shares Out Dil | 99,692 | 84,695 | 83,554 | 74,952 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,196 | $1,044 | $69 | $6,485 |
| Interest Expense | $133 | $176 | $355 | $581 |
| Depreciation & Amortization | $2,162 | $2,215 | $2,359 | $2,406 |
| EBITDA | -$48,618 | -$51,832 | -$68,026 | -$70,006 |
| % Margin | -178% | -350.2% | -1,728.7% | – |